Financing co-led by new investor BRM Group and existing investor Pontifax. Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatm ...

Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected ...

Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and ...